Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome

Economic Evaluation ◽

Lung Injury ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Trial ◽

Beta Agonist ◽

Double Blind ◽

Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: A randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome

Trials ◽

10.1186/1745-6215-12-113 ◽

2011 ◽

Vol 12 (1) ◽

Cited By ~ 16

Author(s):

Gavin D Perkins ◽

Simon Gates ◽

Sarah E Lamb ◽

Chris McCabe ◽

Duncan Young ◽

...

Keyword(s):

Lung Injury ◽

Respiratory Distress ◽

Intravenous Infusion ◽

Distress Syndrome ◽

Beta Agonist ◽

Trial Protocol ◽

Double Blind ◽

A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome

http://isrctn.org/> ◽

10.1186/isrctn38366450 ◽

2013 ◽

Author(s):

Fang Gao

Keyword(s):

Respiratory Distress ◽

Intravenous Infusion ◽

Distress Syndrome ◽

Controlled Trial ◽

Double Blind ◽

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00440-9 ◽

2021 ◽

Cited By ~ 1

Author(s):

Aurélien Mazeraud ◽

Matthieu Jamme ◽

Rossella Letizia Mancusi ◽

Claire Latroche ◽

Bruno Megarbane ◽

...

Keyword(s):

Respiratory Distress ◽

Distress Syndrome ◽

Intravenous Immunoglobulins ◽

Phase 3 ◽

Double Blind ◽

Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease

American Heart Journal ◽

10.1016/j.ahj.2020.05.010 ◽

2020 ◽

Vol 226 ◽

pp. 60-68 ◽

Cited By ~ 4

Author(s):

D. H. Frank Gommans ◽

Joris Nas ◽

Sara-Joan Pinto-Sietsma ◽

Yvonne Koop ◽

Regina E. Konst ◽

...

Keyword(s):

Clinical Trial ◽

Respiratory Distress ◽

Randomized Clinical Trial ◽

Distress Syndrome ◽

Hospitalized Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Infection Disease

A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome

Intensive Care Medicine ◽

10.1007/s001340101077 ◽

2001 ◽

Vol 27 (10) ◽

pp. 1578-1583 ◽

Cited By ~ 57

Author(s):

Jean-Louis Vincent ◽

Rainer Brase ◽

Frederick Santman ◽

Peter Suter ◽

Angela McLuckie ◽

...

Keyword(s):

Respiratory Distress ◽

Prostaglandin E1 ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED. STUDY OF LIPOSOMAL PROSTAGLANDIN E1 (TLC C-53) IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME

Critical Care Medicine ◽

10.1097/00003246-199901001-00486 ◽

1999 ◽

Vol 27 (Supplement) ◽

pp. 164A ◽

Cited By ~ 3

Author(s):

Jean-Louis Vincent ◽

Rainer Brase ◽

Jean-Francois Dhainaut ◽

Angela McLuckie ◽

Frederik Santman ◽

...

Keyword(s):

Respiratory Distress ◽

Prostaglandin E1 ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Protective ventilation in experimental acute respiratory distress syndrome after ventilator-induced lung injury: a randomized controlled trial

British Journal of Anaesthesia ◽

10.1093/bja/aes230 ◽

2012 ◽

Vol 109 (4) ◽

pp. 584-594 ◽

Cited By ~ 10

Author(s):

L. Uttman ◽

U. Bitzén ◽

E. De Robertis ◽

J. Enoksson ◽

L. Johansson ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Lung Injury ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Trial ◽

Protective Ventilation ◽

Randomized Controlled ◽

Ventilator Induced Lung Injury

Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30470-7 ◽

2021 ◽

Author(s):

Barry Dixon ◽

Roger J Smith ◽

Duncan J Campbell ◽

John L Moran ◽

Gordon S Doig ◽

...

Keyword(s):

At Risk ◽

Respiratory Distress ◽

Distress Syndrome ◽

Phase 3 ◽

Double Blind ◽

Treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study

Journal of Critical Care ◽

10.1016/s0883-9441(97)90029-0 ◽

1997 ◽

Vol 12 (4) ◽

pp. 177-182 ◽

Cited By ~ 104

Author(s):

Guido Domenighetti ◽

Peter M. Suter ◽

Marie-Denise Schaller ◽

Rudolf Ritz ◽

Claude Perret

Keyword(s):

Clinical Study ◽

Respiratory Distress ◽

Distress Syndrome ◽

Double Blind ◽

Double Blind Placebo ◽

Controlled Clinical Study

Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome

Critical Care Medicine ◽

10.1097/00003246-200201000-00001 ◽

2002 ◽

Vol 30 (1) ◽

pp. 1-6 ◽

Cited By ~ 146

Author(s):

◽

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Respiratory Distress ◽

Early Treatment ◽

Distress Syndrome ◽

Controlled Trial